Background: The agglutination-based cross-matching method is sensitive for antibody binding to red blood cells but is only partially predictive of complement-mediated hemolysis, which is important in many acute hemolytic transfusion reactions. Here, we describe complement hemolysis using human erythrocytes (CHUHE) assays that directly evaluate complement-mediated hemolysis between individual serum-plasma and red blood cell combinations. The CHUHE assay is used to evaluate correlations between agglutination titers and complement-mediated hemolysis as well as the hemolytic potential of plasma from type A blood donors.
Study Design And Methods: Plasma or serum from each type A blood donor was incubated with AB or B red blood cells in the CHUHE assay and measured for free hemoglobin release.
Results: CHUHE assays for serum or plasma demonstrate a wide, dynamic range and high sensitivity for complement-mediated hemolysis for individual serum/plasma and red blood cell combinations. CHUHE results suggest that agglutination assays alone are only moderately predictive of complement-mediated hemolysis. CHUHE results also suggest that plasma from particular type A blood donors produce minimal complement-mediated hemolysis, whereas plasma from other type A blood donors produce moderate to high-level complement-mediated hemolysis, depending on the red blood cell donor.
Conclusion: The current results indicate that the CHUHE assay can be used to assess complement-mediated hemolysis for plasma or serum from a type A blood donor, providing additional risk discrimination over agglutination titers alone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.13948 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Etiology and outcomes of kidney-limited and systemic thrombotic microangiopathy.
Mod Pathol
December 2024
Expert Center for Immune-mediated Kidney Diseases and Vasculitis, Maastricht University Medical Center, Maastricht, The Netherlands; Dept. Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands. Electronic address:
The syndromes of thrombotic microangiopathy (TMA) are associated with acute kidney injury and end-stage kidney disease (ESKD). TMAs typically present with thrombocytopenia and microangiopathic hemolytic anemia (i.e.
View Article and Find Full Text PDFCold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia caused by cold-reactive IgM antibodies leading to complement-mediated hemolysis. While CAD-associated venous thromboembolism is recognized, its role in arterial thromboembolic events, particularly ischemic stroke, is poorly defined. We report an 84-year-old woman who developed acute onset upper left extremity weakness following exposure to sub-zero temperatures.
View Article and Find Full Text PDFIntroduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, non-malignant hematologic disease characterized by complement-mediated hemolysis (with or without hemoglobinuria), fatigue, increased susceptibility to thrombosis, and bone marrow dysfunction. The development of complement inhibitors has transformed outcomes for patients with PNH, but patients may still experience pharmacodynamic breakthrough hemolysis (BTH), which can be caused by exposure to a complement amplifying condition (CAC), such as vaccination, infection, or surgery.
Materials And Methods: A 13-member expert panel used a validated methodology (a RAND/UCLA modified Delphi panel) to develop consensus on how to classify pharmacodynamic BTH in patients with complement-inhibitor treated PNH.
Real-World Study of US Adults with Paroxysmal Nocturnal Hemoglobinuria Treated with Pegcetacoplan.
Hematol Rep
October 2024
Mayo Clinic, Rochester, MN 55905, USA.
: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease characterized by complement-mediated hemolysis. OPERA is the first US longitudinal real-world study on C3 inhibitor therapy, known as pegcetacoplan. : OPERA enrolled US patients with PNH, age ≥18, who were prescribed pegcetacoplan, and data were collected from routine care.
View Article and Find Full Text PDFNavigating cold agglutinin-induced hemolytic anemia in developing countries: A case report and literature review.
SAGE Open Med Case Rep
September 2024
Memon Medical Institute Hospital, Karachi, Pakistan.
Article Synopsis
- Cold agglutinin-induced hemolytic anemia poses diagnostic challenges, especially in resource-limited settings like Pakistan, highlighted by a case of a 92-year-old male with severe anemia and altered consciousness.
- Diagnosis was confirmed through positive Direct Coombs test and elevated cold agglutinin titers, demonstrating the importance of specific lab findings in identifying the condition.
- Multidisciplinary management, including blood transfusions and immunosuppressive therapy, resolved the patient's symptoms, underscoring the need for enhanced clinician awareness and timely interventions for better patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!